New quintuple agonist from Eli Lilly! So new it is not yet named.

I've been wondering if amylin is similar to cag or eloralintide.

From the limited reading I did, amylin does seem to give satiety similar to cagrilintide.

That's because cagrilintide basically is amylin, just modified to last longer. For practical purposes they work the same.

Clearly they are going to seek biologic status for this one too simply to preserve their earnings.

I lack your courage here. When molecules become increasingly intricate, I grow less sure that typical labs in China will produce the genuine substance rather than a variant that mimics it in routine analyses while being chemically distinct. The chain of supply conceals the original manufacturer through intermediaries who select the most affordable materials from processors that meet basic quality checks, meaning even a trusted provider could deliver differing results in successive lots.

The whole idea of hitting five receptors at once feels like mostly hype since going after calcitonin does nothing to help drop weight and might even work against it. One compound that hits both amylin receptors and calcitonin only reaches about half the results of another that stays strictly on the amylin side. That leaves the calcitonin piece with no real role either on paper or in practice. Still the overall compound looks intriguing to me. I keep wondering how the design works when the shapes of amylin and the glp-1 gip glucagon pieces differ so much. Seeing how it all fits together in detail would probably clear that up.